BioTrinity hears that corporate venture investment is on the increase
This article was originally published in Scrip
Executive Summary
The BioTrinity conference, which was hosted by the UK's Oxfordshire Bioscience Network in Newbury this week, saw lively debate from traditional venture capital (VC) firms and the corporate venture arms from big pharma companies on the pros and cons of biotechnology companies accepting corporate venture capital.